Approaches to the Treatment of NSCLC Harboring KRAS G12C Mutations

home / insights / approaches-to-the-treatment-of-nsclc-harboring-kras-g12c-mutations

Expert perspectives on the advent of KRAS G12C mutations in non–small cell lung cancer, with a focus on the development of targeted therapies in this setting.

EP. 1: Understanding the Nature of a KRAS G12C Mutation in NSCLC

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 9th 2022

EP. 2: Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 9th 2022

EP. 3: Addressing Inadequate Molecular Testing in Patients With NSCLC

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 16th 2022

EP. 4: Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 16th 2022

EP. 5: Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 23rd 2022

EP. 6: Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 23rd 2022

EP. 7: 2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 30th 2022

EP. 8: KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

Martin Dietrich, MD, PhD;Joshua K. Sabari, MD

December 30th 2022

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

Approaches to the Treatment of NSCLC Harboring KRAS G12C Mutations

Latest Conference Coverage